Yun Peng Liu

Aim: To compare the efficacy, safety, and tolerability of abemaciclib plus endocrine therapy (ET) versus ET alone in postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) from China, Brazil, India, and South Africa. Methods: This randomized, double-blind, phase III study was conducted between 9 December 2016 and 29 March 2019. Postmenopausal women with HR-positive, HER2-negative ABC with no prior systemic therapy in an advanced setting (cohort A) or progression on prior ET (cohort B) received abemaciclib (150 mg twice daily) or placebo plus: anastrozole (1 mg/day) or letrozole (2.5 mg/day) (cohort A) or fulvestrant (500 mg per label) (cohort B). The primary endpoint was progression-free survival (PFS) in cohort A, analyzed using the stratified log-rank test. Secondary endpoints were PFS in cohort B (key secondary endpoint), objective response rate (ORR), and safety. This interim analysis was planned after 119 PFS events in cohort A. Results: In cohort A, 207 patients were randomly assigned to the abemaciclib arm and 99 to the placebo arm. Abemaciclib significantly improved PFS versus placebo (median: not reached versus 14.7 months; hazard ratio 0.499; 95% confidence intervals (CI) 0.346–0.719; p = 0.0001). ORR was 65.9% in the abemaciclib arm and 36.1% in the placebo arm ( p < 0.0001, measurable disease population). In cohort B, 104 patients were randomly assigned to the abemaciclib arm and 53 to the placebo arm. Abemaciclib significantly improved PFS versus placebo (median: 11.5 versus 5.6 months; hazard ratio 0.376; 95% CI 0.240–0.588; p < 0.0001). ORR was 50.0% in the abemaciclib arm and 10.5% in the placebo arm ( p < 0.0001, measurable disease population). The most frequent grade ⩾3 adverse events in the abemaciclib arms were neutropenia, leukopenia, and anemia (both cohorts), and lymphocytopenia (cohort B). Conclusion: The addition of abemaciclib to ET demonstrated significant and clinically meaningful improvement in PFS and ORR, without new safety signals observed in this population. Trial Registration: ClinicalTrials.gov identifier: NCT02763566.

Porous cementitious mixtures were prepared with two different spherical particles: expanded polystyrene (EPS) and superabsorbent polymer (SAP). The effect of EPS and SAP on the compressive strength, ultrasonic transmission, internal relative humidity and hydration degree under different volume fraction were studied. Results indicated that SAP matrix possessed much higher compressive strength (30-60%, 28d), ultrasonic transmission velocity, internal humidity (11-13%RH, 28d) and hydration degree (13-21%, 28d) than EPS matrix, which indicated that the desorption of SAP accelerated the hydration and increased the compactness of the surrounding cement paste. The internal cured pores left by SAP might have been strengthened which was different from ordinary pores produced by EPS.

Carbon nanotube used as cold cathode, the triode FED with staggered gate-electrode layer structure was fabricated with the screen-printing technique and conventional sintering process. Using superior mica plate as gate substrate material, the silver slurry was prepared to form the staggered gate electrode. The insulation layer was also manufactured over the gate substrate surface. The design and fabrication of the staggered gate-electrode layer was described in detail. By means of glass frit, the whole panel structure was vacuum-sealed. With the fabricated staggered gate-electrode layer, the modulation of electron emission from CNT field emitter by the gate voltage was confirmed. The packaged tridoe FED possessed better field emission uniformity, good image display performance and high display image brightness.

With the effective screen-printing technique and high-temperature sintering process, the suspersion gate structure was developed. The silver slurry was printed on the gate substrate to form the gate electrode. Using carbon nanotube as cold field emitter, the triode field emission display (FED) panel was fabricated, and the detailed manufacture process was also presented. The anode back plane, the cathode back plane and spacer combined to device room, in which the suspension gate structure would be included. The distance between the gate electrode and carbon nanotube cathode could be reduced, which could decrease the device manufacture cost because of the small gate voltage. The modulation of emitted electron by the gate voltage would be confirmed, and the field emission characteristics was measured. The sealed FED panel with simple fabrication process and designed structure possessed better field emission uniformity, high display brightness and field emission perofrmance.